The initial reporter received a questionable elecsys anti-hbs result from one patient sample tested on the cobas e 801 analytical unit.The reporter stated that the initial result from the analyzer was deemed a false anti-hbs positive result as the patient has been a chronic hepatitis b carrier for years.The patient sample was then sent to another laboratory that uses an abbott alinity.The reporter stated that they explained the issue to the general practitioner (gp) and it was stated that the patient should be considered a carrier; no incorrect diagnosis was made.On (b)(6) 2023, the initial result from the analyzer was a value of 67 (positive).On (b)(6) 2023, the repeat result from the other laboratory was <2.00 iu/l (negative).This result was in line with the patient's previous results.
|
The investigation reviewed the calibration on 17-nov-2023; the results were valid.The investigation reviewed the qc level 2 data provided; the results were mainly within specifications and stable.However, the results were at the lower limit.The qc level 2 after the calibration (it is assumed that this was on 17-dec-2023) was one of the results at the lower limit; it cannot be excluded that this was on the date of event (18-dec-2023) or if a rerun of qc level 2 was performed.The investigation tested the patient sample for anti-hbs ii using two different lots; the investigation was able to reproduce the customer's results.The investigation used an internal neutralization assay to check for the presence of anti-hbs in the patient sample.The investigation determined that based on the results of the neutralization approach, the positive anti-hbs ii result is assumed to be unspecific/false positive.The event was consistent with a lot-independent interference; single false reactive results can occur.Based on the calibration and qc results at the customer site and the additional testing performed at the investigation site, the reagent performed within specification.Product labeling states: "for diagnostic purposes, the results should always be assessed in conjunction with the patient¿s medical history, clinical examination and other findings." the investigation did not identify a product problem.
|